Of mice and (Wo)men: Is this any way to test a new drug?

Journal of Clinical Oncology

Volumn 26, Issue 6, 2008, Pages 830-832

  Haddad, Tufia C ^a   Yee, Douglas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; KI 67 ANTIGEN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BREAST CANCER; CANCER MODEL; CANCER RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOWN REGULATION; DRUG RESEARCH; EDITORIAL; GENE OVEREXPRESSION; HUMAN; MONOTHERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; XENOGRAFT; ANIMAL; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; METABOLISM; METHODOLOGY; MOUSE; NEOPLASM; NOTE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MICE; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 39749130639     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.9062     Document Type: Editorial

References (15)

1. Sharpless N, DePinho R: The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741-754, 2006
2. Fejzo M, Godfrey T, Chen C, et al: Molecular cytogenetic analysis of consistent abnormalities at 8q12-q22 in breast cancer. Genes Chromosomes Cancer 22:105-113, 1998
3. Johnson J, Decker S, Zaharevitz D, et al: Relationship between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424-1431, 2001
4. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715, 2004
5. Osborne C, Hobbs K, Clark G: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584-590, 1985
6. Bezwoda W, Esser J, Dansey R: The value of estrogen and progesterone receptor determinations in advanced breast cancer. Cancer 68:867-872, 1991
7. Group EBCTC: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
8. Lewis G, Figari I, Fendly B, et al: Differential responses of human tumor cell lines to anti-p185HER-2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993
9. Carter P, Presta L, Gorman C, et al: Humanization of an anti-p185HER-2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285-4289, 1992
10. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
11. Vogel C, Cobleigh M, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
12. Massarweh S, Osborne C, Jiang S, et al: Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER2/neu-positive breast cancer. Cancer Res 66:8266-8273, 2006
13. Guix M, de Matos Granja N, Meszoely I: Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 26:897-906, 2008
14. Dowsett M, Smith I, Ebbs S, et al: Short-term Ki67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951s-958s, 2005
15. Baum M, Budzar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002